{
  "schemaVersion": "orion-company-promise-record-v1",
  "ticker": "VKTX",
  "company": "Viking Therapeutics",
  "url": "https://www.orionbiotechai.com/company/VKTX",
  "generatedFrom": "founder-checked batch, as of 2026-10-12",
  "records": [
    {
      "chainId": "VKTX-03",
      "program": "VK2735 · Maintenance Dosing Data",
      "eventLabel": "Clinical results disclosure",
      "status": "Disclosure found",
      "statusDefinition": "https://www.orionbiotechai.com/orion-methodology.html#promise-status-disclosure-found",
      "firstStated": {
        "statement": "In January 2026, Viking announced completion of enrollment in the maintenance dosing study. The company expects to report the results of the study in 3Q26.",
        "window": "3Q26",
        "documentType": "SEC Form 8-K, Exhibit 99.1",
        "date": "2026-02-11",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm"
      },
      "restatements": [
        {
          "kind": "Statement retained",
          "statement": "In January 2026, Viking announced completion of enrollment in the maintenance dosing study. The company expects to report the results of the study in 3Q26.",
          "window": "3Q26",
          "documentType": "SEC Form 8-K, Exhibit 99.1",
          "date": "2026-04-29",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm"
        },
        {
          "kind": "Statement retained",
          "statement": "VK2735 Maintenance Dosing Data Expected 3Q26",
          "window": "3Q26",
          "documentType": "SEC Form 8-K, Exhibit 99.1",
          "date": "2026-07-29",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm"
        }
      ],
      "disclosure": {
        "statement": "Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company’s maintenance study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.",
        "window": null,
        "documentType": "SEC Form 8-K, Exhibit 99.1",
        "date": "2026-09-22",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm"
      },
      "additionalDisclosures": [
        {
          "statement": "On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.",
          "window": "September 22, 2026",
          "documentType": "SEC Form 8-K (Cover filing)",
          "date": "2026-09-22",
          "dateBasis": "filing_date",
          "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-20260922.htm"
        }
      ],
      "scopeNotes": [
        "Sept 22 reported results from the subcutaneous arms; oral maintenance was described as an upcoming Part 2. On Oct 6 the company started Part 2 (oral and additional subcutaneous regimens) and expects results in 2027. ORION has not yet published a separate record for Part 2.",
        "The Form 10-Q filed 2026-04-30 contains a maintenance study description; no results timing window was located. Omission in this quarterly document does not establish cancellation."
      ],
      "scopeSources": [
        {
          "date": "2026-02-11",
          "documentType": "SEC 8-K, Exhibit 99.1",
          "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm",
          "statement": "monthly subcutaneous dosing, daily oral dosing, and weekly oral dosing"
        },
        {
          "date": "2026-09-22",
          "documentType": "SEC 8-K, Exhibit 99.1",
          "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm",
          "statement": "The company plans to explore oral maintenance dosing regimens in an upcoming part 2 to the current study."
        },
        {
          "date": "2026-10-06",
          "documentType": "Company press release",
          "url": "https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity",
          "statement": "We look forward to reporting the results from Part 2 of this study in 2027."
        },
        {
          "date": "2026-04-30",
          "documentType": "SEC Form 10-Q",
          "url": "https://www.sec.gov/Archives/edgar/data/1607678/000119312526193315/vktx-20260331.htm",
          "statement": null
        }
      ],
      "companyReleases": [
        {
          "date": "2026-10-06",
          "url": "https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity"
        }
      ],
      "secCheckedThrough": "2026-10-08",
      "secScope": "2/11, 4/29, 7/29, 9/22 8-K Exhibit 99.1 and 4/30 10-Q checked for maintenance study results timing.",
      "companyPrCheckedDate": "2026-10-08",
      "companyPrScope": "Viking IR releases of 7/29, 9/22, 10/6 checked. Not all company channels.",
      "founderCheckedDate": "2026-10-08",
      "rowsShown": 1,
      "rowsTotal": 2,
      "citation": "Viking Therapeutics (VKTX) — VK2735 · Maintenance Dosing Data: “3Q26” (SEC Form 8-K, Exhibit 99.1 2026-02-11); statement retained “3Q26” (2026-04-29); statement retained “3Q26” (2026-07-29); disclosure 2026-09-22. Status Disclosure found, checked 2026-10-08. Sources: https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm",
      "corrections": []
    }
  ]
}